VGNOIR operates through a Tri-Phasic Eubiosis Matrix to mechanically obliterate resistant biofilms, facilitate mucosal sealing, and drive deep tissue restoration, ensuring durable resolution of complex vaginal pathologies. Its mechanism combines immediate antimicrobial action with sustained tissue regeneration and microbiome rebalancing.
Allen et al. demonstrated in a rat model of chronic kidney disease that combining the prebiotic fiber inulin with a calcimimetic further suppressed elevated bone turnover while improving cortical bone architecture and mechanical properties. This foundational research underscores the broader biological impact of prebiotics on tissue integrity and cellular regeneration. While the referenced study investigates skeletal health, its findings regarding prebiotic-mediated tissue support are highly relevant to Acemannan’s role within VGNOIR’s Tri-Phasic Eubiosis Matrix. Specifically, Acemannan, a key component of Aloe Vera Ext, functions as a targeted prebiotic to foster a healthy vaginal microbiome, preventing recurrence of dysbiosis. Furthermore, its capacity to stimulate submucosal fibroblasts for collagen and GAGs upregulation is directly analogous to the mechanisms that contribute to improved tissue structure and resilience, crucial for addressing conditions such as vaginal laxity and atrophy.
VGNOIR’s comprehensive formulation integrates a clinical-strength inorganic antimicrobial with astringent and restorative botanicals to address the multifactorial nature of vaginal conditions. The inclusion of Aloe Vera Ext, specifically its Acemannan component, is pivotal in facilitating long-term mucosal healing and eubiosis, complementing the immediate eradication of pathogens by Boric Acid and Tea Tree Oil, and the rapid astringent effect of Quercus. This strategy ensures a sustained restoration of vaginal health, moving beyond transient symptom relief. Importantly, VGNOIR is strictly contraindicated during pregnancy due to the presence of a clinical-strength inorganic antimicrobial. Given the oral toxicity of Boric acid, it must be kept strictly out of reach of children and separate from oral medications to prevent accidental ingestion. Furthermore, VGNOIR should not be used in the presence of active, open vaginal ulcerations or severe mucosal lacerations, as this may increase the risk of systemic absorption of the inorganic core.
Q: How does VGNOIR address the challenging issue of chronic recurrence in vaginal infections and atrophy?
A: VGNOIR’s Phase III, powered by Acemannan from Aloe Vera Ext, directly targets recurrence by stimulating collagen and GAG production for deep tissue restoration, while simultaneously functioning as a prebiotic to selectively feed native Lactobacillus, thereby re-establishing a robust, protective vaginal microbiome.
Q: What specific safety considerations are paramount when prescribing VGNOIR?
A: VGNOIR is strictly contraindicated during pregnancy, and due to Boric acid’s oral toxicity, it must be kept out of reach of children. It is also crucial to avoid use in the presence of active vaginal ulcerations or severe mucosal lacerations to prevent systemic absorption risks.
